Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently disclosed stock transactions in a filing with the Securities and Exchange Commission. On February 13, ...

Stephen A. Sherwin, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.4 billion biopharmaceutical company with strong financials and a healthy current ratio of 3.4, sold 13,831 shares of ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

This educational supplement is based on a press release statement from Neurocrine Biosciences and aims to enhance clinical practice and patient care for those affected by classic CAH. According to ...

Neurocrine Biosciences emphasizes the importance of this development for individuals with CAH and their families, as well as healthcare providers. The new treatment options represent an ...

Ashley Allan is making history in her role as executive director for CAH brand marketing at Neurocrine Biosciences, overseeing a cross-functional team that launched the first treatment for CAH (a ...

CEO Kyle Gano highlighted Neurocrine's transformation into a fully ... citing its groundbreaking profile for congenital adrenal hyperplasia (CAH). CFO Matt Abernethy projected INGREZZA sales ...

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research ... Crinessity in congenital adrenal hyperplasia (CAH), the data on patient starts and revenue is ...

Neurocrine Biosciences emphasizes the importance of this development for individuals with CAH and their families, as well as healthcare providers. The new treatment options represent an advancement in ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...